CJC-1295 vs Tesamorelin: Research Comparison

Research use only. This compound is sold strictly for laboratory and in-vitro research. It is not a drug, supplement, food, or cosmetic, is not approved by the FDA, is not intended to diagnose, treat, cure, or prevent any disease, and is not for human or animal consumption. Dosing figures are reference values from the research literature for laboratory models only.

CJC-1295 vs Tesamorelin at a glance

	CJC-1295	Tesamorelin
Also known as	with or without DAC	GHRH analog
Category	Growth Hormone & Muscle	Fat Loss & Weight Management
Format	SubQ	SubQ
Research level	Beginner	Intermediate
Research sizes	2 mg vial, 5 mg vial	5 mg vial, 10 mg vial
In one line	A GHRH analog studied for growth-hormone-release research, with and without DAC.	A GHRH analog studied for visceral-fat and metabolic research.

What is CJC-1295?

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It is studied in two forms: "no DAC" (also called Mod GRF 1-29), which is short-acting, and "with DAC" (Drug Affinity Complex), which binds albumin for a markedly longer half-life in research models.

CJC-1295 research focuses on stimulation of the pituitary to release growth hormone in pulses. The DAC version extends the active window, while the no-DAC version produces a sharper, shorter pulse often studied alongside a GHRP such as Ipamorelin for synergistic release.

What is Tesamorelin?

Tesamorelin is a stabilized analog of growth-hormone-releasing hormone studied for its reported effect on visceral adipose tissue - the fat surrounding internal organs - in metabolic research models.

Tesamorelin stimulates endogenous GH release like other GHRH analogs, with research focused specifically on visceral-fat endpoints rather than subcutaneous fat.

Key research differences

The two are best understood by what each is studied for. CJC-1295: The DAC form trades fewer administrations for a longer, flatter profile; the no-DAC form is studied for sharper, more physiologic pulses. Choice depends on the research kinetics of interest. Tesamorelin: Tesamorelin is studied for visceral fat specifically, distinguishing it from AOD 9604 (general lipolysis) and the GLP-1 peptides (appetite).

How researchers choose between them

CJC-1295 and Tesamorelin belong to different research categories (Growth Hormone & Muscle versus Fat Loss & Weight Management), so they are usually chosen for different research questions rather than as direct substitutes. Some protocols study them together to cover complementary endpoints. Whichever you select, compare on verified quality: both are third-party tested to a 99%+ purity target with a COA on request.

Order CJC-1295 or Tesamorelin

Both available research-grade with a COA on request.

See pricing & sizes

Frequently asked questions

What is the difference between CJC-1295 and Tesamorelin?

CJC-1295 a GHRH analog studied for growth-hormone-release research, with and without DAC; Tesamorelin a GHRH analog studied for visceral-fat and metabolic research. They belong to different research categories (Growth Hormone & Muscle vs Fat Loss & Weight Management). Both are research-use-only.

Can CJC-1295 and Tesamorelin be studied together?

In some research designs, yes - they cover different endpoints, so a protocol may include both. Any combination work is laboratory research only.

Which is better, CJC-1295 or Tesamorelin?

Neither is universally "better" - the right choice depends on the research question. Match the compound to your model's target signal, and compare suppliers on verifiable third-party purity, not sticker price.

All comparisons · CJC-1295 · Tesamorelin · CJC-1295 cost

External references: Peptide (Wikipedia) · U.S. Food and Drug Administration

Both compounds are sold for laboratory and research use only and are not for human or animal consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.